Retrospective Study
Copyright ©The Author(s) 2016.
World J Gastrointest Surg. Jun 27, 2016; 8(6): 452-460
Published online Jun 27, 2016. doi: 10.4240/wjgs.v8.i6.452
Table 5 Prognostic factors of overall survival: Univariate and multivariate analysis
Variable5 yr overall survival (%)Univariate P valueOverall survival HR (95%CI)Multivariate P value
Age ≥ 65 vs < 6550.9 vs 68.3< 0.00111.4557 (1.083-1.9568)0.0032
Gender (male vs female)60.6 vs 600.921--
Lap vs converted vs open70.5 vs 61.8 vs 52.70.0161-0.148
ASA 1/2 vs 3/462.6 vs 45.70.0161-0.131
NeoadjChemo (yes vs no)59.5 vs 60.40.36--
NeoadjRT (yes vs no)66.7 vs 60.20.654--
AdjChemo (yes vs no)40.8 vs 70.5< 0.0011-0.06
AdjRT (yes vs no)53.2 vs 62.30.206--
TNM stage (I-IV)< 0.0011< 0.0012
Stage I77.2Reference
Stage II73.81.04 (0.58-1.84)0.907
Stage III60.31.52 (0.89-2.58)0.124
Stage IV13.95.80 (3.26-10.33)< 0.001
Tumor grade0.00210.0152
Well differentiated75Reference
Moderately differentiated60.12.10 (1.00-4.40)0.049
Poorly differentiated39.11.18 (0.54-2.54)0.682
CRM < 2 mm vs > 2 mm40.1 vs 63.5< 0.00111.66 (1.19-2.32)0.0032
No. of lymph nodes ≥ 12 vs < 1262.2 vs 56.10.08--
Perineural invasion36.2 vs 67.3< 0.0011-0.276
Vascular emboli46.2 vs 68.5< 0.0011-0.14
Clinical symptoms of obstruction at presentation (yes vs no)35.3 vs 64.6< 0.00111.95 (1.39-2.74)< 0.0012